{"name":"CSPC Megalith Biopharmaceutical Co.,Ltd.","slug":"cspc-megalith-biopharmaceutical-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"A zoster mRNA vaccine SYS6017","genericName":"A zoster mRNA vaccine SYS6017","slug":"a-zoster-mrna-vaccine-sys6017","indication":"Prevention of herpes zoster (shingles) in adults","status":"phase_2"},{"name":"Enlonstobart injection","genericName":"Enlonstobart injection","slug":"enlonstobart-injection","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"A zoster mRNA vaccine SYS6017","genericName":"A zoster mRNA vaccine SYS6017","slug":"a-zoster-mrna-vaccine-sys6017","phase":"phase_2","mechanism":"SYS6017 is an mRNA vaccine that encodes varicella-zoster virus (VZV) antigens to stimulate adaptive immune responses against herpes zoster.","indications":["Prevention of herpes zoster (shingles) in adults"],"catalyst":""},{"name":"Enlonstobart injection","genericName":"Enlonstobart injection","slug":"enlonstobart-injection","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxPSTIzR292ZjJlcW5SaFloNFFQa1lVZHdxTUFjOU9kRXhqNVBlN2pld09Gd2FESVVMeU1FcFZOczJocFA0X0d3NjBjVFJzTUJNSGRybGZ0S1dXczdpeGJ5QUpOS1FCRVdXZ2dEbzdTaklZbHdLQTJtem9aSzFKS0V0T0FWN2s4NHJjQUo1UTE5RXFQeEtF?oc=5","date":"2025-06-16","type":"pipeline","source":"BioWorld News","summary":"Astrazeneca makes $5.3B drug R&D pact with CSPC - BioWorld News","headline":"Astrazeneca makes $5.3B drug R&D pact with CSPC","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxPVGhudTlQdmVrczBXOEY2Z3pDTmNKSWhVNXZvM3Jka1Y3VkhKMFdZYzIyaE9fb240SklNeVhWWWppRFhERWNOZ0FSQ2d6eU9zc2JaWmdqMWdkc1Nub1pXOHk5dkpGNk1kcXJkbjJBVzZGS041dkg1ODJsYUxCOGE2bkMzMzF2RUgyTlFsZXQtOFU2VFdPenk4dzBYQ0FoVl9wWnhMT1RZSm8zZw?oc=5","date":"2025-06-10","type":"deal","source":"BioWorld News","summary":"Ligachem inks two mystery ADC deals with CSPC subsidiary Novarock - BioWorld News","headline":"Ligachem inks two mystery ADC deals with CSPC subsidiary Novarock","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxNdE9HcGNzbVcwQ09OU1VSSWxGbTZxZXd0YXZDZks3akRFMndBb25OZ01waHV1RXZmOXFWWGtqUmpHclFEeWRzS1ZXM2JPbkp5M0V6T291cVNFYTFVYnBuZ3B0am1ka3JkanJENWlRaUVQcG9nc290WlpzMFVkenRZcmFKTktETG95ckNzNkhqNjZHZXZfTWJ2VzkwSUZyd2pPbUEwVjMzbw?oc=5","date":"2025-06-03","type":"deal","source":"BioWorld News","summary":"CSPC hints at three upcoming deals worth $5B for EGFR ADC, others - BioWorld News","headline":"CSPC hints at three upcoming deals worth $5B for EGFR ADC, others","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxQVHI4MG5idDZaMUVwODRYVXZIcEhlbFlOaFpvQkVVaDdwNFMzYmdURWlkY3JHM01LX2dSY01HdXU3MG9wYjFtSUcyU2VGVGd6amJYc2tnQVpEd3R0dlE2aHhLMEF1ZXFYN29OVlRldzYtd25VdmtWWjE4a1RJNFZKbXpwNGU4ZGxDc0lmdmY1LWFTSkRmNi1TU05wTQ?oc=5","date":"2025-06-03","type":"pipeline","source":"BioWorld News","summary":"Astellas nabs Evopoint’s CLDN18.2-targeting ADC for $1.34B - BioWorld News","headline":"Astellas nabs Evopoint’s CLDN18.2-targeting ADC for $1.34B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxQTTFwVmV0RHdQTjN3cmtDUk93d0I4ODhqYnEtNE1YV3ZKYWhrcVpsZXRZX1prNHZybkRFU3g0YmlGem1kWGktZXpJU3RwMFhWbk5sS1loNmNxWDNPZnBHeGcyY1Y0Zm0xNUE2aVR1a2drUUtCdDVOOE1OV3c4NnpIcmhpREsyYm16a3AwVXppMU43YmI0?oc=5","date":"2025-02-20","type":"deal","source":"The Pharma Letter","summary":"CSPC Megalith grants license to Radiance Biopharma for ADC - The Pharma Letter","headline":"CSPC Megalith grants license to Radiance Biopharma for ADC","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAJBVV95cUxOTXU3T3haVEFJbml3OVVBRi1semx3N01rYkdHVXl1R19peDJMY3d6YWQ3eFZybG5WTjUtLXVBVzBOVXRyRE1xTXFwdV9SQjdCR2tJS2t5QkdrUlhGa1JRQ1VPejdmUFAycTh3YlAyQWlVUUNwSjRvaGt5ZHN4cklBSURpbnlzOWRQZVZnMzVHazRHUFBjcVdfa3dNUVZuZnBQUG1oUGZ5ZjFqLVhrbVhtZkFyeUFfaEd5eVJoTjdDVldTMVNZUUxET0JiR2pEZ0h1bUk3M1V6LTJVU3hDX1c0YWJzVFNWNDZtc3dPX1VtcGc2QVpHa05wOUdlaUgxb055V2s2V0Y2a1pONC01bEpMcThJYWJfakg3?oc=5","date":"2023-02-13","type":"pipeline","source":"PR Newswire","summary":"Corbus Pharmaceuticals expands oncology pipeline with the addition of a clinical stage Nectin-4 targeting Antibody Drug Conjugate (ADC) - PR Newswire","headline":"Corbus Pharmaceuticals expands oncology pipeline with the addition of a clinical stage Nectin-4 targeting Antibody Drug ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAJBVV95cUxPc1dWZTVqbUUwMnVJMEstTjVWZHc3RGhiamRLaEtzVTR1aV9rR0pheTRWeXBQM1ozUk1sd1VzOFR0U0RfNVNHZWxoZl9falMyUkt1YWs0SXBKQV9TTVg4OVF1aldIVmY2X0hnM09fWGNDMHRFX21EVlRtdktYU3VKTWVnVjhlZ1pjQ3dzbXlJTHZZUWJEc0tDa19VX3pHUzNyYnJvUTNoSjQ4bS1CTV9wM2h3WTZaWlZVMnZHVW14MHY3MnoyNFVmVk9SZXJaMUpPNXhlR2ZqUHdma1BvMTVGcVFzMm03ZlV5NGJXMmxzbFAtU3d1NDlJUEEzQ1l5dDh5MFJVM1FRcHBkaExTbW1NNGEtUEVWbE5XcnA2MEJpYy1lSDFJTmpMckRJOU9yUXlORkIzNnQzWTVfN0QzemtjWVRsYzc3VERBS3JrVw?oc=5","date":"2022-07-28","type":"pipeline","source":"PR Newswire","summary":"Elevation Oncology Expands Pipeline through Exclusive Licensing of EO-3021 (SYSA1801), a Clinical Stage Anti-Claudin18.2 Antibody Drug Conjugate, From CSPC Pharmaceutical Group - PR Newswire","headline":"Elevation Oncology Expands Pipeline through Exclusive Licensing of EO-3021 (SYSA1801), a Clinical Stage Anti-Claudin18.2","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxOSzBkYzhLRlFtbG05TDRPbzBGSDVyQ2RYdkxRUzd2YlRIRzkwZExoZ1JWWDVpdDMtbC1iT2NmOE5GSmVBY0FnM0dqd0pnSUxkTTQzNURpeU1ucU52QmQtVE1raFZtam9pSHI4b3l6UGRyWmRjYkhzQUNJNm1heFhoY2ZCdy1yV0RWRHBnZWhabm1pQVpmZ3pjQmY3cTFzbC1LZFc4UzBwODNkM0lsQ1E?oc=5","date":"2022-07-28","type":"deal","source":"BioWorld News","summary":"CSPC grants Elevation Oncology global rights to ADC drug in $1.2B deal - BioWorld News","headline":"CSPC grants Elevation Oncology global rights to ADC drug in $1.2B deal","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":2},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}